Show simple item record

dc.contributor.authorMathur, Ruchi
dc.contributor.authorLevin, Olga
dc.contributor.authorAzziz, Ricardo
dc.date.accessioned2010-11-17T20:16:05Z
dc.date.available2010-11-17T20:16:05Z
dc.date.issued2008-08-27en_US
dc.identifier.issn1176-6336en_US
dc.identifier.pmid18728832en_US
dc.identifier.urihttp://hdl.handle.net/10675.2/174
dc.description.abstractPolycystic ovary syndrome (PCOS) is one of the most common endocrine/metabolic disorders found in women, affecting approximately 105 million women worldwide. It is characterized by ovulatory dysfunction, often presenting as oligomenorrhea or amenorrhea and either clinical or biochemical hyperandrogenism. Combined oral contraceptive (COC) therapy has long been a cornerstone of care for women with PCOS. COC therapy often provides clinical improvement in the areas of excessive hair growth, unpredictable menses, acne, and weight gain. One of the main issues in COC therapy is choosing the most appropriate progestin component to provide the greatest anti androgenic effects. Drospirenone, a relatively new progestin, has shown benefit in the PCOS population when used in conjunction with ethinyl estradiol. We now review the role of COCs in PCOS, focusing specifically on drospirenone. Controversy over metabolic effects of COCs in PCOS is also discussed.
dc.description.urihttp://www.dovepress.com/articles.php?article_id=1317en_US
dc.publisherDove Medical Pressen_US
dc.rightsThe PMC Open Access Subset is a relatively small part of the total collection of articles in PMC. Articles in the PMC Open Access Subset are still protected by copyright, but are made available under a Creative Commons or similar license that generally allows more liberal redistribution and reuse than a traditional copyrighted work. Please refer to the license statement in each article for specific terms of use. The license terms are not identical for all articles in this subset.en_US
dc.titleUse of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome.en_US
dc.identifier.pmcidPMC2504056en_US
dc.contributor.corporatenameCedars-Sinai Medical Center, Los Angeles, CAen_US
refterms.dateFOA2019-04-09T16:32:43Z
html.description.abstractPolycystic ovary syndrome (PCOS) is one of the most common endocrine/metabolic disorders found in women, affecting approximately 105 million women worldwide. It is characterized by ovulatory dysfunction, often presenting as oligomenorrhea or amenorrhea and either clinical or biochemical hyperandrogenism. Combined oral contraceptive (COC) therapy has long been a cornerstone of care for women with PCOS. COC therapy often provides clinical improvement in the areas of excessive hair growth, unpredictable menses, acne, and weight gain. One of the main issues in COC therapy is choosing the most appropriate progestin component to provide the greatest anti androgenic effects. Drospirenone, a relatively new progestin, has shown benefit in the PCOS population when used in conjunction with ethinyl estradiol. We now review the role of COCs in PCOS, focusing specifically on drospirenone. Controversy over metabolic effects of COCs in PCOS is also discussed.


Files in this item

Thumbnail
Name:
tcrm-0402-487.pdf
Size:
102.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record